A Scalable Platform with Structural Advantage
Unlike genomics-only approaches, which predict response based on mutation patterns, fScreen directly measures drug efficacy in real patient cells. Built on standardized high-throughput flow cytometry and integrated analytics software, fResolve, the platform is engineered to enable:
Transforming Cancer Treatment with Functional Precision
exalt® is building the next generation of precision oncology—moving beyond genomic probability toward direct, functional measurement of treatment response.
Our proprietary platform, fScreen, is testing how a patient’s living tumor cells respond to more than 100 approved cancer drugs at single-cell resolution. Within 72 hours, oncologists will receive a ranked, actionable treatment profile—enabling evidence-based therapy selection tailored to the individual patient.
In clinical studies, fScreen-guided therapy has demonstrated significantly improved response rates in late-stage hematologic cancers, validating the power of functional precision medicine.
The right drug,
for the right patient,
at the right time
Our Vision
exalt® aims to make functional precision diagnostics the global standard of care—reducing ineffective treatments, improving patient outcomes, and unlocking a new data-driven era of oncology.
News
Clinical trials
Publications
Team
Tea Pemovska, PhD
CSO
co-founder
Gabriela Staber, Dr. iur LLM
Legal
co-founder
Alexander Pichler, MD
CEO
co-founder
